恒瑞医药：注射用SHR-A2102等多款产品获药物临床试验批准

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for multiple clinical trial applications for new drugs, indicating progress in its research and development pipeline [1] Group 1: Clinical Trial Approvals - The company’s subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., and Shanghai Heng Rui Medicine Co., Ltd. received approval for the clinical trial of SHR-A2102 [1] - The same subsidiaries also received approval for clinical trials of SHR-A2102, Adebeli monoclonal antibody injection, and SHR-1802 [1] - Guangdong Heng Rui Medicine Co., Ltd. received approval for the clinical trial of SHR-1905 injection [1]